연구동향 분석

증례 : Etanercept로 치료 중인 강직성척추염 환자에서 발생한 폐 크립토코쿠스증 1예

임채호 ( Chae Ho Lim ) 이상헌 ( Sang Heon Lee ) 김호연 ( Ho Youn Kim ) 김완섭 ( Wan Seop Kim ) 강성희 ( Seong Hui Kang ) 권세웅 ( Se Woong Kwon ) 김지완 ( Ji Wan Kim ) 박수연 ( Soo Youn Park ) 안상희 ( Sang Hee An ) 유형민 ( Hyung Min Yu ) 김해림 ( Hae Rim Kim ) 2014년

논문상세정보
인용/피인용
' 증례 : Etanercept로 치료 중인 강직성척추염 환자에서 발생한 폐 크립토코쿠스증 1예' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • ankylosing spondylitis
  • etanercept
  • pulmonarycryptococcosis
  • tumor necrosis factor inhibitor
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
35 0

0.0%

' 증례 : Etanercept로 치료 중인 강직성척추염 환자에서 발생한 폐 크립토코쿠스증 1예' 의 참고문헌

  • 류마티스관절염 환자에서 Etanercept 사용 중 발생한 Candida Parapsilosis 윤활낭염 1예
    이광선 대한류마티스학회지 15 (2) : 175 ~ 179 [2008]
  • 류마티스 관절염 환자에서 발생한 식도 아스페르길루스증 1예
    박혜성 Infection and Chemotherapy 39 (6) : 327 ~ 331 [2007]
  • Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis
    Machado MA Rheumatol Int 33 : 2199 ~ 2213 - [2013]
  • Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha
    Gorman JD N Engl J Med 346 : 1349 ~ 1356 - [2002]
  • Treatment benefit or survival of the fittest: what drives the time-dependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient?
    Strangfeld A Ann Rheum Dis 70 : 1914 ~ 1920 - [2011]
  • RATIO group. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry
    Salmon-Ceron D Ann Rheum Dis 70 : 616 ~ 623 - [2011]
  • Novel future therapeutic options in myasthenia gravis
    Dalakas MC Autoimmun Rev 12 : 936 ~ 941 - [2013]
  • Non-viral opportunistic infections in new users of tumour necrosis factor inhibitor therapy: results of the SAfety Assessment of Biologic ThERapy (SABER)Study
    Baddley JW Ann Rheum Dis [2013]
  • Localized cutaneous Cryptococcus albidus infection in a 14-year-old boy on etanercept therapy
    Hoang JK Pediatr Dermatol 24 : 285 ~ 288 - [2007]
  • Innovative uses of tumor necrosis factor alpha inhibitors
    Mazza J Dermatol Clin 28 : 559 ~ 575 - [2010]
  • Infectious Diseases
    Jonathan C Mosby Elsevier : 1823 ~ 1852 [2010]
  • Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists
    Bergstrom L Arthritis Rheum 50 : 1959 ~ 1966 - [2004]
  • Fungal infections complicating tumor necrosis factor alpha blockade therapy
    Tsiodras S Mayo Clin Proc 83 : 181 ~ 194 - [2008]
  • Evidence of a role of tumor necrosis factor alpha in refractory asthma
    Berry MA N Engl J Med 354 : 697 ~ 708 - [2006]
  • 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis
    Braun J Ann Rheum Dis 70 : 896 ~ 904 - [2011]